You just read:

European Hematology Association: Two is better than one: The Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Rapid Tumor Responses in a Phase 2 Study for Relapsed/Refractory NHL

News provided by

European Hematology Association

Jun 23, 2017, 02:30 ET